Introduction
============

Celiac disease (CD) is a common autoimmune disorder characterized by gluten-induced systemic symptoms and signs, presence of specific antibodies and specific human leukocyte antigen type, and characteristic histological changes in the duodenum. At the onset, patients may present typical manifestation (diarrhea, weight loss), may be oligosymptomatic, or may present atypical symptoms such as headache and psychiatric disturbances,[@b1-ndt-13-1211] including eating disorders (EDs).[@b2-ndt-13-1211] Anorexia nervosa (AN) is one of the most common psychiatric diagnoses in adolescent girls (\<1%--4% of the female population). It is a serious, potentially life-threatening ED characterized by self-starvation, with important weight loss associated with an intense fear of weight gain and persistent behavior to prevent weight gain and by self-esteem overly related to body image.[@b3-ndt-13-1211] AN presents usually in the adolescence with symptoms partially overlapping CD (in particular, weight loss and psychiatric disorders), but the relationship between these two conditions has received little attention in the literature,[@b4-ndt-13-1211] with few case reports and small case series published,[@b4-ndt-13-1211],[@b5-ndt-13-1211] again often in adult patients.[@b6-ndt-13-1211] Only recently, Basso et al[@b7-ndt-13-1211] reported the prevalence of CD in a population of 177 adolescents affected by AN (males and females, restrictive and binge/purging type) and found that the overall prevalence of CD in their sample was the same as that in the general population (1:100/200).[@b7-ndt-13-1211] They concluded that AN patients may not require regular screening for CD. On the other hand, a recent meta-analysis highlighted the greater presence (5.3%--44.4%) of EDs in population with gastrointestinal disorders, including CD.[@b8-ndt-13-1211]

Undiagnosed CD predisposes to mental and behavioral disorders, and great attention should be maintained to exclude this illness in subjects with AN.[@b7-ndt-13-1211] Moreover, the association with CD might represent a biological and psychological prognostic risk factor for subjects affected by AN of the restrictive type (Anr), since the two conditions might mutually reinforce their clinical expression.

The main objective of this study was to assess whether the prevalence of CD in adolescents with ANr is higher than that reported in the general population, requiring a regular screening program. Moreover, another aim of this study was to determine a possible association between CD and baseline ANr-related clinical features.

Materials and methods
=====================

Eighty-two adolescent female outpatients and inpatients consecutively accessing to the Eating Disorder Service of the Child and Adolescent Mental Health Department of Monza (Italy) were enrolled. All the subjects were diagnosed with ANr according to the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* criteria. CD-specific serological tests were performed. In particular, tissue transglutaminase type-2 antibodies (anti-TG2), endomysial antibodies (EMA), and antibodies against deamidated forms of gliadin peptides (DGP) were analyzed to assess CD. If any total antibody determination was over the laboratory cutoff, a second determination distinguishing IgA and IgG subtypes was performed. IgA deficiency was investigated as well according to guidelines.[@b9-ndt-13-1211],[@b10-ndt-13-1211] Moreover, to assess the specific ED features and the presence of depressive traits at the time of blood withdrawal, patients completed the Italian-validated version of Eating Disorder Inventory-3[@b11-ndt-13-1211] and of the Children's Depression Inventory.[@b12-ndt-13-1211] The research was approved by the institutional review board of A.S.S.T. Monza (Healthcare System of Regione Lombardia -- San Gerardo Hospital). All subjects and their parents were asked to sign an informed consent to participate in the study.

Statistical analysis
--------------------

Continuous variables were expressed as mean ± standard deviation (SD), whereas categorical variables were expressed as percentages. Analysis of variance was used for the analysis of continuous variables, and the nonparametric Spearman test was used for the analysis of correlations. The level of significance was set at *P*\<0.05. Analysis was completed using Statistical Package for the Social Sciences statistical package (Version 21.0; IBM Corporation, Armonk, NY, USA).

Results
=======

Clinical and demographic data of the recruited sample are shown in [Table 1](#t1-ndt-13-1211){ref-type="table"}. Three patients (3.7%) of our series (AN CD+) were already diagnosed with a biopsy-proven CD before arriving to our attention for the ANr diagnosis and were under a gluten-free diet; for this reason, we reported them separately. Anti-TG2 serology allowed the identification of two patients (2.4%) who were eventually diagnosed with CD following a duodenal biopsy (AN+). Eight additional patients (9.8%) presented with anti-DGP antibodies above cutoff values (AN− DGP+). None of them presented anti-EMA and, at the time, no further investigations were performed. In the remaining 69 cases (84.1%, AN−), CD serology was not significant. Neither age, disease duration, body mass index (BMI), Eating Disorder Inventory-3-specific subscores, and composites nor Children's Depression Inventory was significantly associated with any CD measure or characterized as a specific group.

Discussion
==========

The results of the present study suggest that CD serology might not be useless in Eating Disorders Services as a screening strategy in ANr for detecting mimics or comorbidities even if our figures are higher than those expected in the general population (2.4% new diagnosis vs 1%).[@b7-ndt-13-1211] As suggested by Urban-Kowalczy,[@b13-ndt-13-1211] the screening for CD would be recommended in AN patients in which the symptoms, such as digestive complaints, are only partially responding to psychiatric interventions. We sought to identify those AN patients carrying any CD-antibody positivity, besides a full CD diagnosis, since many psychiatric conditions, including EDs,[@b2-ndt-13-1211] have been variably associated with the presence of these antibodies, as well as diffuse brain changes.[@b14-ndt-13-1211] None of the predetermined clinical characteristics could appreciably distinguish AN− patients from AN− DGP+ ones; furthermore, the five CD-diagnosed AN adolescents did not clinically differ in a significant manner from the other recruited patients. Nevertheless, different from data obtained by Basso et al[@b7-ndt-13-1211] in a more heterogeneous sample of adolescents with EDs, our results suggest the presence of a slight clinical overlap with CD in the presentation of ANr in female adolescent patients. In a clinical perspective, the comorbidity of CD might increase the medical complications of ANr.[@b3-ndt-13-1211] Moreover, alimentation and digestion in adolescents with ANr and CD might represent a biological and psychological *locus minoris resistentiae* (ie, weakness), from both a biological and psychological point of view. ANr and CD could mutually reinforce their clinical expression: as it occurs in other somatic conditions, such as weight control through insulin underdosing in anorexic subjects with type 1 diabetes,[@b3-ndt-13-1211] we observed the deliberate gluten intake as a weight-loss strategy in one case of celiac subjects with ANr. Certainly, the major caveat is that our report is underpowered for detecting a meaningful difference in this sense and the research should be repeated with an adequate number of subjects. Even Ricca et al[@b15-ndt-13-1211] stressed the importance of future investigations because of the clinical significance and prognosis of AN, together with the possible diagnostic problems related to the similarity of many of the symptoms that characterize AN and CD. Moreover, we studied adolescents with ANr, but we did not exclude the opportunity of analyzing a possible relationship between CD and other EDs. Possibly, other presentations such as nonceliac gluten sensitivity might be considered for future investigations.[@b16-ndt-13-1211]
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Clinical characteristics of the recruited sample

  Variables                     AN−                     AN+            AN CD+             AN− DGP+
  ----------------------------- ----------------------- -------------- ------------------ ------------------------
  Patients, n (%)               69 (84.1)               2 (2.4)        3 (3.7)            8 (9.8)
  Age, years                    14.5±1.4 (11--17)       13--15         12--13--16         14.8±1 (13--16)
  Duration, months              10.5±9.7 (1--42)        20--5          6--5--7            6.4±5.4 (2--18)
  BMI, kg/m^2^                  15.0±1.8 (10.7--19.7)   13.5--15.4     14.4--14.5--16.7   15.8±2.4 (13.2--19.3)
  EDI3-DT                       64.8±26.5 (0--99)       80--21         68                 57±17.3 (27--75)
  EDI3-B                        32.8±32.0 (0--96)       0--15          0--0--0            28.6±34.9 (0--83)
  EDI3-BD                       59.4±25.7 (17--99)      56--35         8--17--12          49.5±24.7 (14--94)
  EDI3-EDRC                     60.4±24.4 (7--95)       67--71         34--73--85         51.9±21.2 (13--77)
  EDI3-GPMC                     59.1±23.1 (8--99)       18--101        67--73--98         60.5±23.5 (25--85)
  CDI ≥20, n (%)                15 (21.7)               Score: 5--26   20--17--11         2 (25)
  anti-TG2 tot (NV \<15 U/mL)   2.8±2.0 (1--13.7)       62.0--304.7    3.1--7.0--6.8      2.8±1.2 (1.2--4.7)
  anti-TG2 IgA                  NP                      83.9--288.3    NP                 NP
  anti-TG2 IgG                  NP                      11.4--10.1     NP                 NP
  anti-EMA                      Neg                     Pos--pos       Neg--neg--neg      Neg
  anti-DGP tot (NV \<15 U/mL)   6.8±3.2 (1.9--14.3)     39.2--152.1    5.23--4.4--6.1     29.5±6.7 (21.6--41)
  anti-DGP IgA                  NP                      5.7--37.8      NP                 4.8±2.8 (2.1--10.5)
  anti-DGP IgG                  NP                      32.2--\>100    NP                 40.8±22.2 (10.4--66.1)
  IgA tot (NV: 61--348 mg/dL)   155.4±66 (0--371)       103--172       125--195--99       189±95.9 (77--333)
  IgA deficiency, n (%)         2 (3.1)                 Neg--neg       Neg--neg           Neg
  Duodenal biopsy               NP                      Pos--pos       Pos--pos           NP

**Note:** Continuous data are reported as mean ± standard deviation (range).

**Abbreviations:** AN, anorexia nervosa; BMI, body mass index; CD, celiac disease; CDI, Children's Depression Inventory; DGP, deamidated forms of gliadin peptides; EDI3, Eating Disorder Inventory-3; -B, bulimia; -BD, body dissatisfaction; -DT, drive for thinness; -EDRC, eating disorder risk composite; -GPMC, general psychological maladjustment composite; EMA, endomysial antibodies; NP, not performed; NV, normal values; TG2, tissue transglutaminase type-2; pos, positive; neg, negative; tot, total.
